Price
$0.29
Increased by +0.05%
Dollar Volume (20D)
187.32 K
ADR%
16.65
Earnings Report Date (estimate)
Aug 7, 23 (N/A)
Market Cap.
4.38 M
Shares Float
13.83 M
Shares Outstanding
15.10 M
Beta
1.81
Price / Earnings
-0.24
BPR
7.21
20D Range
0.20 0.34
50D Range
0.18 0.34
200D Range
0.18 1.90
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 14, 22 -0.50
Decreased by -2.40 K%
-0.02
Decreased by -120.00 K%
Aug 9, 22 -0.01
Increased by +50.00%
-0.01
Decreased by -7.49 K%
May 16, 22 -0.02
Increased by 0.00%
-0.02
Mar 29, 22 -0.04
Decreased by -300.00%
-0.02
Decreased by -5.00 K%
Nov 10, 21 -0.02
Increased by +93.33%
-0.02
Aug 4, 21 -0.02
Increased by 0.00%
-0.02
May 5, 21 -0.02
Increased by +50.00%
-0.02
Mar 3, 21 -0.01
Increased by 0.00%
-0.01
Decreased by -7.49 K%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 23 0.00
Decreased by N/A%
-3.67 M
Increased by +34.83%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0.00
Decreased by N/A%
-2.10 M
Increased by +66.18%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0.00
Decreased by N/A%
-6.49 M
Decreased by -78.91%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-2.10 M
Increased by +40.89%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-5.64 M
Decreased by -53.78%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-6.22 M
Decreased by -34.81%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-3.63 M
Decreased by -7.72%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-3.56 M
Decreased by -30.21%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.